Simulation of Human Intravenous and Oral Pharmacokinetics of 21 Diverse Compounds Using Physiologically Based Pharmacokinetic Modelling
The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Background The importance of predicting human pharmacokinetics during compound selection has been recognized in the pharmaceutical industry. To this end there are many different approaches that are applied.Methods In this study we compared the accuracy of physiologically based pharmacokinetic (PBPK) methodologies implemented in GastroPlus™ with the one-compartment approach routinely used at Pfizer for human pharmacokinetic plasma concentration-time profile prediction. Twenty-one Pfizer compounds were selected based on the availability of relevant preclinical and clinical data. Intravenous and oral human simulations were performed for each compound. To understand any mispredictions, simulations were also performed using the observed clearance (CL) value as input into the model.Results The simulation results using PBPK were shown to be superior to those obtained via traditional one-compartment analyses. In many cases, this difference was statistically significant. Specifically, the results showed that the PBPK approach was able to accurately predict passive distribution and absorption processes. Some issues and limitations remain with respect to the prediction of CL and active transport processes and these need to be improved to further increase the utility of PBPK modelling. A particular advantage of the PBPK approach is its ability to accurately predict the multiphasic shape of the pharmacokinetic profiles for many of the compounds tested.Conclusion The results from this evaluation demonstrate the utility of PBPK methodology for the prediction of human pharmacokinetics. This methodology can be applied at different stages to enhance the understanding of the compounds in a particular chemical series, guide experiments, aid candidate selection and inform clinical trial design.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“PBPK verification practice has adopted the same bound, so agreement at this level reflects the practical resolution of the methods rather than genuine mechanistic identity [18,64,100,102,103].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [103]
In the citing paper
“The approximately 2-fold window is the conventional acceptance criterion for human pharmacokinetic prediction rather than an arbitrary cut-off: retrospective evaluations of clearance and volume predictions report that the better allometric and IVIVE methods typically recover observed human values to within about 2-fold.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [103]
In the citing paper
“Prediction accuracy is optimised by considering all available preclinical data [19], filling identified data gaps and verifying the preclinical PBPK model [18].”
In the citing paper
“Physiologically based pharmacokinetic modelling has been shown to be superior to empirical scaling [16, 18], but the benefits of the PBPK approach go beyond the accuracy of the prediction to include an improved mechanistic understanding.”
In the citing paper
“Renal [39, 40] and biliary [41] elimination involving active transport are also challenging to model mechanistically from in-vitro data, and, in general, prediction of human pharmacokinetics for transported molecules is difficult because absorption, distribution and elimination can all be affected [18].”
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Physiological Parameter Values for Physiologically Based Pharmacokinetic Models
Brown, R. P., Delp, M. D., Lindstedt, S. L., Rhomberg, L. R., & Beliles, R. P. (1997) · Toxicology and Industrial Health · doi:10.1177/074823379701300401 · Cited by 1,415
Obach, R. S. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)14938-0 · Cited by 1,232
Rodgers, T., & Rowland, M. (2006) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20502 · Cited by 946
Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance
Brian Houston, J. (1994) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)90520-7 · Cited by 925
Rodgers, T., Leahy, D., & Rowland, M. (2005) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20322 · Cited by 776
Predicting the Impact of Physiological and Biochemical Processes on Oral Drug Bioavailability
Agoram, B., Woltosz, W. S., & Bolger, M. B. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(01)00179-x · Cited by 651
Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics
Boxenbaum, H. (1982) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01062336 · Cited by 648
Poulin, P., & Theil, F. (2002) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10005 · Cited by 568
The Simcyp ® Population-based ADME Simulator
Jamei, M., Marciniak, S., Feng, K., Barnett, A., Tucker, G., & Rostami-Hodjegan, A. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250802691074 · Cited by 533
A compartmental absorption and transit model for estimating oral drug absorption
Yu, L. X., & Amidon, G. L. (1999) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(99)00147-7 · Cited by 455
Cited by
Basic Concepts in Physiologically Based Pharmacokinetic Modeling in Drug Discovery and Development
Jones, H., & Rowland‐Yeo, K. (2013) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1038/psp.2013.41 · Cited by 626
Self-citationJones, H., Chen, Y., Gibson, C., Heimbach, T., Parrott, N., Peters, S., Snoeys, J., Upreti, V., Zheng, M., & Hall, S. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.37 · Cited by 488
“Confidence is generally higher for Biopharmaceutics Classification System class 1 and 2 molecules that are also predominantly eliminated by cytochrome P450 (CYP) oxidation and this is discussed in more detail in the section about Challenges and Future Opportunities for the Application of PBPK Models.10,31,32 Once clin…”
BackgroundSelf-citationImpact of a five-dimensional framework on R&D productivity at AstraZeneca
Morgan, P., Brown, D. G., Lennard, S., Anderton, M. J., Barrett, J. C., Eriksson, U., Fidock, M., Hamrén, B., Johnson, A., March, R. E., et al. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.244 · Cited by 452
Predicting Clearance Mechanism in Drug Discovery: Extended Clearance Classification System (ECCS)
Varma, M. V., Steyn, S. J., Allerton, C., & El-Kattan, A. F. (2015) · Pharmaceutical Research · doi:10.1007/s11095-015-1749-4 · Cited by 334
PBPK models for the prediction of in vivo performance of oral dosage forms
Kostewicz, E. S., Aarons, L., Bergstrand, M., Bolger, M. B., Galetin, A., Hatley, O., Jamei, M., Lloyd, R., Pepin, X., Rostami-Hodjegan, A., et al. (2014) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2013.09.008 · Cited by 315
“…theoretical models with a mechanistic oral absorption model of gut physiology results in simulations that explain experimental observations and are predictive of preclinical and human BA and pharmacokinetics (Bungay et al., 2011; Jones et al., 2011a,b; Watson et al., 2011; Yamazaki et al., 2011).”
BackgroundMethod
Metadata
- Authors
- Jones, H. M., Gardner, I. B., Collard, W. T., Stanley, P. J., Oxley, P., Hosea, N. A., Plowchalk, D., Gernhardt, S., Lin, J., Dickins, M., Rahavendran, S. R., Jones, B. C., Watson, K. J., Pertinez, H., Kumar, V., & Cole, S.
- Affiliations
- Pfizer (United Kingdom) (GB)
- Pfizer (United States) (US)
- Corresponding author
- Jones, Hannah M.
- Venue
- Clinical Pharmacokinetics
- Published
- 2011-05
- Volume
- 50
- Issue
- 5
- Pages
- 331-347
- ISSN
- 0312-5963 (ISSN-L)
- OpenAlex
- W2074689515
- Cited by
- 110
- References
- 40
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 7 · 2023: 12 · 2022: 7 · 2021: 5 · 2020: 6 · 2019: 3 · 2018: 6 · 2017: 8 · 2016: 5 · 2015: 9 · 2014: 7 · 2013: 9 · 2012: 17
- FWCI
- 10.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Pharmacokinetics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Topics
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Keywords
- physiologically based pharmacokinetic modelling, GastroPlus, intravenous administration, oral administration, plasma concentration-time curve, passive absorption, active transport, drug clearance, candidate selection
- MeSH terms
- Administration, Oral, Animals, Computer Simulation, Dogs, Pharmaceutical Preparations, Half-Life, Humans, Injections, Intravenous, Metabolic Clearance Rate, Microsomes, Liver, Models, Biological, Pharmacokinetics, Retrospective Studies, Species Specificity, Area Under Curve, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Simulation of Human Intravenous and Oral Pharmacokinetics of 21 Diverse Compounds Using Physiologically Based Pharmacokinetic Modelling. https://app.cochat.ai/papers/10.2165/11539680-000000000-00000
- The paper
- Jones, H. M., Gardner, I. B., Collard, W. T., Stanley, P. J., Oxley, P., Hosea, N. A., Plowchalk, D., Gernhardt, S., Lin, J., Dickins, M., Rahavendran, S. R., Jones, B. C., Watson, K. J., Pertinez, H., Kumar, V., & Cole, S. (2011). Simulation of Human Intravenous and Oral Pharmacokinetics of 21 Diverse Compounds Using Physiologically Based Pharmacokinetic Modelling. Clinical Pharmacokinetics. https://doi.org/10.2165/11539680-000000000-00000
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.